Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force

Chubak J, Kamineni A, Buist DS, Anderson ML, Whitlock EP
Record ID 32015001085
English
Authors' objectives: We conducted this systematic evidence review on aspirin use for the prevention of CRC to support the U.S. Preventive Services Task Force (USPSTF) in updating its previous recommendation. Our review addressed four key questions in adults without a history of CRC, familial adenomatous polyposis, or Lynch Syndrome: 1) Does regular aspirin use reduce CRC mortality or all-cause mortality? 2) Does regular aspirin use reduce the incidence of CRC? 3) Does regular aspirin use reduce the incidence of colorectal adenoma? 4) What are the harms of regular aspirin use for the prevention of colorectal cancer?
Authors' recommendations: Aspirin appears to reduce the risk of CRC incidence after an induction and latency period of approximately 10 years, with a similar effect on CRC mortality. The applicability of data for long-term effects of low-dose aspirin on CRC mortality, however, is limited, particularly in the context of a population selected for primary CVD prevention. Aspirin does not appear to have a strong effect on all-cause mortality within 10 years of initiating use, and data on longterm cumulative risk of all-cause mortality were sparse.
Details
Project Status: Completed
URL for project: http://www.ncbi.nlm.nih.gov/books/NBK321661/
Year Published: 2015
URL for published report: http://www.ncbi.nlm.nih.gov/books/NBK321661/pdf/Bookshelf_NBK321661.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Humans
  • Aspirin
  • Colorectal Neoplasms
  • Preventive Medicine
Contact
Organisation Name: Agency for Healthcare Research and Quality
Contact Address: Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name: martin.erlichman@ahrq.hhs.gov
Contact Email: martin.erlichman@ahrq.hhs.gov
Copyright: Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.